RespireRx Pharmaceuticals Inc (fka RSPI)

[meixatech]

“The problem here is that the subjects who took the drug slept less. This is the most robust finding of the study (p<0.001).”

From the release:

“Sleep efficiency, the percent of time asleep while in bed for the eight hour session, was significantly (p<0.001) reduced by about 20% after administration of CX1739, although the level of daytime sleepiness, determined by the Clinical Global Impressions Daytime Vigilance test given the morning following treatment, was unaffected by CX1739.”

One can conclude from this that CX1739 allows the subject to reduce sleep time and still maintain a daytime wakefulness, at least for the onetime dose. If this effect is long term without side effects, it would have great potential in a number of different areas (college, military etc.)